2024 Cohort
Introduction
We’ve all got to start somewhere. We recognise that one of the best ways to ensure the continued growth and success of the UK life science sector is to provide an encouraging and supportive environment within which our very early-stage ventures can stress test their science and business ideas. A good cohort isn’t just about great science – it’s about people, making connections and a shared bond centred around wanting to make a difference. For this reason, our cohorts are always a diverse group with a range of different life and work experience. The 2024 cohort was no exception! Meet them here…
Athernal
Athernal is developing new vaccines designed to lower the risk of cancer and other age-related diseases. Its approach focuses on targeting early indicators of cancer with novel vaccine techniques to eliminate them, aiming to improve patient outcomes.
enstic
enstic is dedicated to transforming the understanding and management of insect populations through innovative sensor-based devices to provide real-time, data-driven insights into ecological impacts and health risks they cause.
Ephyra
Ephyra is developing an innovative sponge RNA technology that targets microRNA disease drivers to restore cellular health during disease.
New Platelet Company
The New Platelet Company manufactures universal platelets for transfusion from induced pluripotent stem cells to add to the supply of platelets from donors, which is not sufficient to treat all patients at risk of bleeding.
OvartiX
OvartiX is a women's health drug discovery company that harnesses large-scale human multi-omics data, state-of-the-art cell engineered and animal models to identify, validate and develop next-generation therapeutics for female reproductive disorders.
U-Ploid biotechnologies ltd
U-Ploid biotechnologies ltd develops next-generation IVF therapeutics for treating female infertility by improving the egg quality within the IVF cycle, generating more eggs capable of supporting a healthy pregnancy.